Pliant Therapeutics Stock Statistic Functions Linear Regression Intercept
| PLRX Stock | USD 1.41 0.08 6.02% |
| Symbol |
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Linear Regression Intercept is the expected mean value of Pliant Therapeutics price seriese where values of its benchmark or peer price series are zero.
Pliant Therapeutics Technical Analysis Modules
Most technical analysis of Pliant Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Pliant from various momentum indicators to cycle indicators. When you analyze Pliant charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. Pliant Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people. As a micro-cap equity, Pliant Therapeutics is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/B of 0.41. Pliant Therapeutics has a market cap of 82.96 M, ROE of -64.27%.
Methodology
Unless otherwise specified, financial data for Pliant Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Pliant (USA Stocks:PLRX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Pliant Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Pliant Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial BoardSome investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pliant Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pliant Therapeutics' short interest history, or implied volatility extrapolated from Pliant Therapeutics options trading.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Artificial Intelligence Invested few shares | |
 | Warren Buffett Holdings Invested over 20 shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Adviser Favorites Invested few shares | |
 | Blockchain Invested few shares | |
 | Corona Opportunity Invested few shares | |
 | Driverless Cars Invested few shares | |
 | Hedge Favorites Invested over 200 shares | |
 | Advertising Invested few shares | |
 | Momentum Invested over 20 shares | |
More Resources for Pliant Stock Analysis
Reviewing Pliant Therapeutics commonly begins with financial statements and performance trends. Financial ratios provide context for profitability, efficiency, and growth trends. Selected reports below provide context for Pliant Stock:Pliant Therapeutics has a market cap of 82.96 M, ROE of -64.27%. See Your Equity Center for portfolio-level analysis. This suggests a position in Pliant Therapeutics within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. Our How to Buy Pliant Stock guide explains the steps to invest in Pliant Therapeutics stock.Analysis related to Pliant Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Investors evaluate Pliant Therapeutics using market value and book value, each describing different facets of the business. Pliant Therapeutics' market capitalization is 82.96 M. A P/B ratio of 0.41 suggests Pliant Therapeutics trades near or below book value. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
The concept of value for Pliant Therapeutics differs from its quoted price, since each reflects a different lens. For Pliant Therapeutics, key inputs include a P/B ratio of 0.41, and ROE of -64.27%. Trading price represents the transaction level agreed by market participants.